Magenta Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of MGTA-145, a First-Line Stem Cell Mobilization Product Candidate

CAMBRIDGE, MA, USA I April 24, 2019 I Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that it has dosed the first subjects in a Phase 1 study of MGTA-145. Magenta intends to develop MGTA-145 in autoimmune diseases, blood cancers and genetic diseases.

More than 85 percent of the 65,000 transplants in the US and Europe each year use mobilized hematopoietic stem cells as a cell source. MGTA-145 is a biologic chemokine factor that Magenta is developing as a first-line therapy for stem cell mobilization. MGTA-145 is designed to enable single-day mobilization and collection of high numbers of stem cells without G-CSF, the current standard of care. MGTA-145 works synergistically with plerixafor, another stem cell mobilization product.

The Phase 1 study will investigate the safety and tolerability of MGTA-145 alone and in combination with plerixafor in healthy volunteers and establish recommended Phase 2 doses. The study will also measure the number of hematopoietic stem cells in the blood after dosing with MGTA-145 alone and in combination with plerixafor.

“There is a clear need for a better first-line stem cell mobilization agent for both patients and donors that does not involve the use of G-CSF,” said John DiPersio, M.D., Ph.D., Professor of Medicine, Washington University School of Medicine. “G-CSF requires five to seven days of injections in order to provide adequate numbers of stem cells for transplant. There are significant side effects associated with G-CSF, including severe bone pain that may require the use of narcotic pain medications. A significant portion of patients do not mobilize an adequate number of stem cells with G-CSF alone and require a second drug and more days of stem cell collection. Further, approximately fifty percent of donors decline to donate for patients undergoing allogeneic transplant, in part because of the burden associated with donation with current mobilization regimens.”

“MGTA-145 was developed based on our understanding of the physiological mechanisms that control stem cell mobilization. Preclinical data suggest that MGTA-145 in combination with plerixafor could reliably provide a robust number of stem cells in a single day for both autologous and allogeneic stem cell transplant. The cells that are mobilized have been shown to contain a large number of high-quality stem cells, which is associated with better disease outcomes,” said John Davis, M.D., M.P.H., Chief Medical Officer, Magenta Therapeutics. “We believe that MGTA-145 has the potential to become a new first-line standard of care for stem cell mobilization that could improve stem cell collection for more patients and donors.”

SOURCE: Magenta Therapeutics

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up